Lycopene
In clinical developmentRecent clinical, regulatory, research and industry developments relating to this drug.
The Relationship Between Lycopene and Metabolic Diseases.
R01 CA90759: The Effects of Lycopene on High Risk Prostatic Tissue
Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma
Efficacy of Oral Lycopene in the Management of Oral Lichen Planus
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes5
Journals, researchers & institutions
- Nutrients1
- Cielecka-Piontek J1
- Czerny B1
- Kamiński A1
- Kulawik A1
- Zalewski P1
- Independent Public Clinical Hospital No. 11
- Institute of Natural Fibres and Medicinal Plants1
- Pomeranian Medical University in Szczecin1
- Poznan University of Medical Sciences1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 5 of the same disease areas as Lycopene in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials